1 recruiting, 1 suspended, 1 unknown. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Suspended 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow AVENIO ctDNA Surveillance Kit: new trials by email Literature Review of AVENIO ctDNA Surveillance Kit trials Research Report on AVENIO ctDNA Surveillance Kit
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC Durvalumab, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer, NSCLC, Stage III | Phase 3 | Recruiting | Stanford University | 48 | 2021-08-25 | 2026-09-30 |
| Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy - Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I | Phase 2 | Suspended | Stanford University | 80 | 2021-04-08 | 2026-07-07 |
| Potential Clinical Utilities of Circulating Tumor DNA in Gastric Cancer AVENIO ctDNA surveillance kit - Gastric Cancer | Unknown | Shanghai Zhongshan Hospital | 55 | 2018-12-01 | 2019-06-27 |
Carcinoma, Non-Small-Cell Lung (2) · Stomach Neoplasms (1)
Stanford University (2) · Shanghai Zhongshan Hospital (1)
United States (2) · China (1)
Joel W Neal, MD,PhD (1) · Maximilian Diehn, MD (1) · Zhaoqing Tang, MD (1)